PubRank

Kazutaka Higaki

Author PubWeight™ 42.72‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm 2003 1.26
2 Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int J Pharm 2007 1.20
3 Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release 2006 1.15
4 Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos 2002 1.03
5 Gastrointestinal transit and drug absorption. Biol Pharm Bull 2002 1.01
6 Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): in vivo evaluation. J Control Release 2006 0.99
7 Skin permeation of propranolol from polymeric film containing terpene enhancers for transdermal use. Int J Pharm 2004 0.97
8 PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int J Pharm 2011 0.96
9 Pre-coating with serum albumin reduces receptor-mediated hepatic disposition of polystyrene nanosphere: implications for rational design of nanoparticles. J Control Release 2004 0.94
10 Albumin-conjugated PEG liposome enhances tumor distribution of liposomal doxorubicin in rats. Int J Pharm 2007 0.93
11 Effect of coupling of albumin onto surface of PEG liposome on its in vivo disposition. Int J Pharm 2006 0.92
12 Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm Res 2003 0.92
13 Fetuin mediates hepatic uptake of negatively charged nanoparticles via scavenger receptor. Int J Pharm 2006 0.91
14 In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells. J Control Release 2008 0.90
15 Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors. Int J Pharm 2008 0.89
16 Prolongation of residence time of liposome by surface-modification with mixture of hydrophilic polymers. Int J Pharm 2008 0.88
17 In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol. J Control Release 2008 0.86
18 Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine. J Control Release 2005 0.86
19 Hepatic uptake of negatively charged particles in rats: possible involvement of serum proteins in recognition by scavenger receptor. J Control Release 2004 0.86
20 Quantitative evaluation of PEPT1 contribution to oral absorption of cephalexin in rats. Pharm Res 2008 0.83
21 Development of suppository formulation safely improving rectal absorption of rebamipide, a poorly absorbable drug, by utilizing sodium laurate and taurine. J Control Release 2004 0.82
22 Evaluation of in vivo dissolution behavior and GI transit of griseofulvin, a BCS class II drug. Int J Pharm 2007 0.81
23 Analysis and prediction of absorption behavior of colon-targeted prodrug in rats by GI-transit-absorption model. J Control Release 2003 0.81
24 Pharmacokinetics and safety of resveratrol derivatives in humans after oral administration of melinjo (Gnetum gnemon L.) seed extract powder. J Agric Food Chem 2014 0.80
25 Prediction of plasma concentration-time curve of orally administered theophylline based on a scintigraphic monitoring of gastrointestinal transit in human volunteers. Int J Pharm 2002 0.80
26 Effects of temperature, growth phase and luxO-disruption on regulation systems of toxin production in Vibrio vulnificus strain L-180, a human clinical isolate. World J Microbiol Biotechnol 2013 0.79
27 Optimization of suppository preparation containing sodium laurate and taurine that can safely improve rectal absorption of rebamipide. Biol Pharm Bull 2006 0.79
28 Transport of D-glucose across cultured stratified cell layer of human oral mucosal cells. J Pharm Pharmacol 2002 0.79
29 Appearance of double peaks in plasma concentration-time profile after oral administration depends on gastric emptying profile and weight function. Pharm Res 2007 0.79
30 Development of transdermal therapeutic formulation of CNS5161, a novel N-methyl-D-aspartate receptor antagonist, by utilizing pressure-sensitive adhesives I. Biol Pharm Bull 2012 0.79
31 Combinatorial use of sodium laurate with taurine or L-glutamine enhances colonic absorption of rebamipide, poorly absorbable antiulcer drug, without any serious histopathological mucosal damages. J Pharm Sci 2003 0.79
32 Involvement of intracellular Ca2+ dynamics in cytoprotective action by amino acids and cytotoxicity by sodium laurate, an absorption enhancer. J Pharm Sci 2006 0.79
33 Novel oral absorption system containing polyamines and bile salts enhances drug transport via both transcellular and paracellular pathways across Caco-2 cell monolayers. Int J Pharm 2008 0.79
34 Evaluation of sustained release suppositories prepared with fatty base including solid fats with high melting points. Int J Pharm 2004 0.78
35 Deeper penetration into tumor tissues and enhanced in vivo antitumor activity of liposomal paclitaxel by pretreatment with angiogenesis inhibitor SU5416. Mol Pharm 2012 0.78
36 Mechanisms of cytoprotective effect of amino acids on local toxicity caused by sodium laurate, a drug absorption enhancer, in intestinal epithelium. J Pharm Sci 2002 0.78
37 In vitro evaluation of the ciliary beat frequency of the rat nasal epithelium using a high-speed digital imaging system. Biol Pharm Bull 2013 0.78
38 Animal models for predicting potency of oral sustained-release adhesive microspheres in humans. Int J Pharm 2006 0.77
39 Antimalarial activity of endoperoxide compound 6-(1,2,6,7-tetraoxaspiro[7.11]nonadec-4-yl)hexan-1-ol. Parasitol Int 2011 0.77
40 Novel oral formulation safely improving intestinal absorption of poorly absorbable drugs: utilization of polyamines and bile acids. J Control Release 2006 0.77
41 Analysis and prediction of absorption behavior for theophylline orally administered as powders based on gastrointestinal-transit-absorption (Gita) model. Drug Metab Pharmacokinet 2002 0.77
42 Important role of serum proteins associated on the surface of particles in their hepatic disposition. J Control Release 2002 0.77
43 Determinants for in vivo antitumor effect of angiogenesis inhibitor SU5416 formulated in PEGylated emulsion. J Pharm Sci 2014 0.77
44 Nanoparticle-based passive drug targeting to tumors: considerations and implications for optimization. Biol Pharm Bull 2013 0.76
45 Effect of percutaneous endoscopic gastrostomy on gastrointestinal motility: evaluation by gastric-emptying scintigraphy. Nucl Med Commun 2008 0.76
46 Prediction of oral absorption of griseofulvin, a BCS class II drug, based on GITA model: utilization of a more suitable medium for in-vitro dissolution study. J Control Release 2007 0.76
47 Major determinants in hepatic disposition of polystyrene nanospheres: implication for rational design of particulate drug carriers. Crit Rev Ther Drug Carrier Syst 2002 0.76
48 Antimalarial activity of 6-(1,2,6,7-tetraoxaspiro[7.11]nonadec-4-yl)hexan-1-ol (N-251) and its carboxylic acid derivatives. Parasitol Int 2011 0.76
49 Novel comb-shaped PEG modification enhances the osteoclastic inhibitory effect and bone delivery of osteoprotegerin after intravenous administration in ovariectomized rats. Pharm Res 2012 0.75
50 Improvement of Oral Bioavailability of N-251, a Novel Antimalarial Drug, by Increasing Lymphatic Transport with Long-Chain Fatty Acid-Based Self-Nanoemulsifying Drug Delivery System. Pharm Res 2015 0.75
51 Establishment of novel prediction system of intestinal absorption in humans using human intestinal tissues. J Pharm Sci 2013 0.75
52 In vitro evaluation of nasal mucociliary clearance using excised rat nasal septum. Biol Pharm Bull 2012 0.75
53 Amino acids suppress apoptosis induced by sodium laurate, an absorption enhancer. J Pharm Sci 2009 0.75
54 Evaluation of factors affecting gastrointestinal absorption of a novel anticoagulant FX-93 for development of oral formulation. J Pharm Sci 2012 0.75
55 Design of controlled-release morphine suppositories containing polyglycerol ester of fatty acid. Biol Pharm Bull 2005 0.75
56 Casein enhances stability of peptides in intestinal lumen: role of digested products of casein. Pharm Res 2003 0.75
57 Formulation and evaluation of paclitaxel-loaded polymeric nanoparticles composed of polyethylene glycol and polylactic acid block copolymer. Biol Pharm Bull 2012 0.75
58 Importance of bile acids for novel oral absorption system containing polyamines to improve intestinal absorption. J Control Release 2006 0.75
59 Evaluation of inhibitory activity of casein on proteases in rat intestine. Pharm Res 2003 0.75
60 Up-regulation of P-glycoprotein expression in small intestine under chronic serotonin-depleted conditions in rats. J Pharmacol Exp Ther 2004 0.75
61 Aminoalkylmethacrylate copolymer E improves oral bioavailability of YM466 by suppressing drug-bile interaction. J Pharm Sci 2013 0.75
62 Sex differences in pharmacokinetics of cilostazol in rats. Xenobiotica 2011 0.75
63 Effect of adrenergic stimulation on drug absorption via passive diffusion in Caco-2 cells. Int J Pharm 2008 0.75